Turing Refuses to Cut Price of Lifesaving Drug Daraprim

People most likely to contract the infection are organ transplant and HIV patients – and pregnant women, because it can kill their baby.

The company has now stated that the price of the pills for patients will stay the same, with a reduction in price for hospitals only.

Those sales were not a factor in the pricing strategy of Turing, said its Chief Marketing Officer on Wednesday. That drives up future treatment and insurance costs. The chairman of the HIV Medicine Association, Dr. Carlos del Rio has called Turing’s changes “just window dressing”.

The price-gauging company said cutting the list price was less important than reducing the cost to hospitals.

Turing, which has offices in Switzerland and NY, bought the rights to market Daraprim this past August in the USA, when it did not have any competition.

After receiving a lot of criticism, the 32-year-old, who is the CEO of Turing Pharmaceuticals, announced that the price hike would not happen, which diminished his haters to a certain extent.

Michael Graae/For New York Daily News Martin Shkreli recently went back on his promise that he would lower the price of Daraprim, a life-saving drug for AIDS.

KaloBios, which Shkreli took control of after the company said it would wind down operations on November 13, has now seen the price of its stock rise about 2,500% in just a few days.

But on Wednesday his company said in a press release that it would drop prices by 50 percent for hospitals, create smaller bottles with 30 pills and provide free starter packs in 2016.

Imprimis also has begun selling capsules of another drug whose price was jacked up and is considering doing the same with dozens of now high-priced generic drugs for pain, heart disease, infections, skin and hormonal conditions and immune disorders.

The company is now working with the Food and Drug Administration to get the compound drug covered by both Medicare and private insurers.

The boss of a drug company which increased the cost of lifesaving HIV-treating medication by 5,000 per cent has been accused of not honouring a pledge to cut the drug’s price to patients.

“He was feeling great on Monday” at a check-up, with his symptoms much reduced, Dinges said.